A 002 - eTheRNA Immunotherapies
Alternative Names: A-002 - eTheRNA ImmunotherapiesLatest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator eTheRNA Immunotherapies
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Head and neck cancer